-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target

Benzinga·06/23/2026 11:43:51
Listen to the news
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $6 price target.